After SC insulin injection or CSII, intravenous (IV) insulin was tapered, and glucose was infused to clamp plasma glucose at 130 mg/dl for 24 h. Onset of action (defined as reduction of IV insulin >50%) was earlier with NPH (0.8 +/- 0.2 h), CSII (0.5 +...
There was no statistically significant difference in the time-course of the blood glucose levels after administration of NPH human insulin and NPH PPI. A tendency was noted, however, that NPH human insulin has a faster onset of action and that the serum glucose minimum for NPH human insulin ...
The potential benefits of rapid-acting insulin analogs versus regular human insulin are that the analogs have earlier onset and peak of biologic activity, resulting in lower postprandial glucose levels; a shorter duration of action, resulting in less late-prandial hypoglycemia; and less biologic variab...
Insulin glargine is a basal insulin analogue with a longer duration of action and smoother time–action profile than NPH [8]. Studies comparing sulfonylurea or sulfonylurea and metformin combined with insulin glargine have consistently found similar overall glycaemic control, similar insulin doses, but...
To describe clinical outcomes in youth with new-onset type 1 diabetes mellitus (T1DM) treated with a modified, twice-daily regimen of a mixture of NPH insulin and rapid-acting insulin analogue at breakfast and separate injections of rapid-acting insulin analogue and insulin detemir at dinner. Our...
tients to contrast the onset of end of action, action, Commentary: Achieving adequate glycemic control and duration of action of the established basal re- can be for fami- extremely frustrating patients, their and with and their healthcare placement insulins, NPH, ultralente, CSII...
There was no difference as to the duration of action. This is contrary to some earlier reports stating that protamine-bound biosynthetic human insulin has a shorter duration of action than porcine preparations. The onset of the hypoglycaemic action in type IIa diabetics is significantly more rapid ...
Perinatal outcomes associated with the use of glargine during pregnancy Insulin glargine (IG), with its non-peaking action profile, might be useful in diabetic pregnancy. However, data on its safety are limited and its use duri... GD Cianni,E Torlone,C Lencioni,... - 《Diabetic Medicine》...
Summary Aims In intensified insulin therapy, the recent development of short-acting insulin analogues with a very rapid onset of action forces a new discu... GA Brunner,S Hirschberger,G Sendlhofer,... - 《Diabetic Medicine A Journal of the British Diabetic Association》 被引量: 99发表: 2010...